APOA1 and coronary artery disorder: However, despite the promising in vivo findings as MDCO-216 [52], CSL-111 [56] and CER-001 [53] infusions increased apoA-I plasma levels and enhanced HDL-C cholesterol efflux capacity in healthy volunteers and CHD patients, they failed to achieve a significant regression in coronary atherosclerosis when tested in clinical trials [11,53,56,57].